Comparative genomic hybridization (CGH) was developed to identify pathogenic DNA copy-number changes (e.g., duplications, deletions) on a genome-wide scale, and to map these changes to genomic ...

Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkin's Lymphoma Genomic losses were ...

Agilent Technologies Inc. and Cogenics, a division of Clinical Data, Inc. have announced that Cogenics has been recertified, for the third year, as a Certified Microarray Service Provider for Agilent ...